(Length of Discussion: 5 min)

Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma.  A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting.   In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1 with an anti-VEGF agent in first line metastatic renal cell carcinoma. It was theorized that atezolizumab’s T cell mediated cancer cell killing may be enhanced through bevacizumab’s reversal of VEGF mediated immunosuppression. 

In the IMmotion 151 trial, patients were enrolled who were treatment naïve regardless of MSKCC risk group to atezolizumab 1200mg IV q 3 weeks + bevacizumab 15 mg/kg IV q3 weeks or sunitnib 50mg PO daily 4 week on/2week off.  Patients were stratified by PD-L1 status (<1% vs >1%).  Primary endpoints included progression free survival (PFR) in PD-L1 positive patients and overall survival in an intention to treat analysis.

Thomas Keane further details the specifics of the IMmotion 151 trial including secondary endpoints, the predetermined cutoff date, and baseline characteristics.  In summary, the IMmotion 151 trial met its primary PFS endpoint in the PD-L1 positive patients with atezolizumab + bevacizumab compared to sunitinib with fewer high grade adverse reactions.  This data does support atezolizumab + bevacizumab as first line therapy in metastatic clear cell renal cell.  We look forward for the data to continue to mature to help patient outcomes in this space. 


Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS 

Read More Related Content:

IMmotion 151: A randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]

Complete ASCO GU 2018 Meeting Coverage